Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rep. Shimkus, Author Of 'Cures' Device Provisions, Joins Exodus Of Republicans Retiring In 2020 From US House

Executive Summary

Illinois Rep. John Shimkus, a well-known pro-medtech industry bill sponsor, announced on 30 August his plans for a January 2020 retirement. He joins at least 15 Republican House members who recently said they are also ending their Capitol Hill careers, leaving six vacancies on the US House Energy and Commerce and Ways and Means panels prior to the 2020 elections.

You may also be interested in...

Device Tax-Repeal Bill Introduced In House With 227 Co-Sponsors

US House Representatives Ron Kind, D-Wis., and Jackie Walorski, R-Ind., have introduced a permanent medical device tax-repeal bill, alongside 225 co-sponsors from both parties.

Despite Cures Boost, Lingering Appropriations Means FDA Device Funding Still An Unknown For 2017

With the president's signature of the 21st Century Cures Act, US FDA has $20m in FY 2017 to begin carrying out a multitude of reforms in the law. Meanwhile, the regular budget appropriated by Congress will remain at 2016 levels through April. But as of Dec. 14, device center director Jeff Shuren said he did not know the amounts specifically that would go to his center. And now FDA supporters wonder if the Cures dollars will be tapped to do regular agency work.

Rep. John Shimkus, Architect Of Cures Bill Device Reform Provisions


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts